Researchers at Maryland University have completed an early phase clinical trial to asses the feasibility and preliminary outcomes of treating Bipolar II Disorder with single-dose synthetic psilocybin. Specifically, this recently published study treated patients with a BD II diagnosis in a current depressive episode, excluding those in the manic phase of the disorder. The lead researcher Scott Aaronson, and the study's lead therapist, Tammy Miller, will present the study's findings and be available for questions from all of you. This is an excellent opportunity to learn about the world's first psychedelic therapy trial for people with a bipolar disorder, a patient population that is consistently excluded from these trials for fear of inducing new (hypo)manic or psychotic episodes. A novel application indeed!